MOLECULAR INFORMATION
Molecular information
- Type
- Short peptide bioregulator · claimed pancreatic tissue modulator
Pancragen is one of the Khavinson family of “short bioregulator peptides”.
Claims vs evidence
- Pancreatic tissue support — preclinical only, single-group
- Type 2 diabetes adjunct — claimed; no Western RCT
Why we grade it D
Same single-source evidence pattern as the rest of the family.
Frequently asked questions
- What is Pancragen?
- A short Khavinson-family bioregulator peptide marketed for pancreatic-tissue support. Vendor claims include type 2 diabetes adjunct use and pancreatitis recovery.
- Is Pancragen authorised for diabetes?
- No — not authorised by any major regulator. Type 2 diabetes has well-evidenced treatments (metformin, GLP-1 agonists, etc.); using Pancragen instead is not supported by clinical data.
- Why grade D?
- Single-research-group evidence pattern as the rest of the Khavinson family.